Introduction
The folk acid in man's diet is present in many different forms. The basic 'building block' from which these are derived is pteroylmonoglutamic acid. Dietary folate consists to a large extent of reduced folates (tetrahydro-PteGlu and dhydro-PteGlu), usually carrying a methyl group or other C1 unit, which are to a variable and unknown extent in polyglutamate form. Although PteGlu'') itself is not a major dietary constituent there are reasons for believing that the study of its absorption characteristics may be relevant to normal dietary folate absorption. First, it is probable that polyglutamates are broken down to monoglutamate before absorption (Rosenberg & Godwin, 1971) , and, secondly, the reduced folates, even when carrying a C1 unit (except 5-formyl tetrahydro-PteGlu), are unstable in the presence of oxygen (McIntyre, Dow, McIntyre & Harding, 1975) and therefore much of these folates are likely to be oxidized to PteGlu before absorption.
PteGlu is a weak acid and as such may be absorbed by passive non-ionic diffusion. That the intestinal mucosa is preferentially permeable to non-ionic (or undissociated) forms of weak acids and bases has been shown by Hogben, Tocco, Brodie & Schanker (1959) . If PteGlu were to be absorbed in this way, non-specifically as a weak acid, altering pH would alter its degree of dissociation and alter its rate of absorption. In a study in which jejunal pH was increased above normal by bicarbonate ingestion, a decrease in absorption of PteGlu was found (Benn, Swan, Cooke, Blair, Matty & Smith, 1971) .
The same workers also found that a number of patients with coeliac disease have an abnormally high jejunal intraluminal pH (Benn & Cooke, 1971) . From this it was surmised that abnormally high pH may be responsible for folate malabsorption in coeliac disease. Other workers, however, have found that bicarbonate ingestion does not decrease PteGlu absorption (Perry & Chanarin, 1972) . This study was performed to find out, fmt, whether altering pH in a more directly controlled way had any effect on the absorption of PteGlu and, secondly, whether this is relevant to PteGlu malabsorption in coeliac disease. Some aspects of the mechanism of PteGlu absorption are discussed.
Methods

Perfusion
Jejunal perfusion was performed in human subjects with either a triple-lumen tube or a doublelumen tube with proximal occluding balloon. With the triple-lumen system the proximal mixing segment was 15 cm and with both systems the test segment was 30 cm in length. There were two perfusates. The first contained glucose (56 mmol/l), sodium chloride (122 mmol/l) and pteroylmonoglutaniic acid (68 pmol/l). The PteGlu was labelled with tritium such that the radioactivity of the solution was 400 nCi/l. Phenolsulphonphthalein (14 mmol/l) and polyethylene glycol 4OOO labelled with 14C (10 g/l) were used as non-absorbable water-soluble markers. The second solution was identical with the first except that sodium hydroxide (10 or 20 mmol/l) was present in place of sodium chloride (10 or 20 mmol/l).
The perfusion tube was passed orally and allowed to make its way down through the stomach until the perfusion point was at the ligament of Treitz, as judged radiologically. The perfusate was infused at a constant flow rate of 10 or 15 ml/min at a constant temperature of 37°C. The first solution was used to estimate PteGlu absorption under 'base-line' conditions: after a 50 min equilibration period, three 10 min collections were taken. After this the alkaline solution was introduced, without interrupting the constant flow of the infusion. After 10 min, or however long it took for the fluid aspirated distally to become alkaline, three further 10 min collections were taken to estimate absorption of PteGlu during the alkaline phase.
The pH of the aspirated solutions was measured without delay with a Pye model 290 glass electrode pH meter. The concentration of phenolsulphonphthalein was estimated with a Gilford 300 N spectrophotometer. Concentrations of 4C-labelled polyethylene glycol and 3HH-labelled PteGlu were measured with a Packard Tricarb scintillation counter. From these measurements net water absorption from, or net secretion into, the test segment was calculated. The amount of PteClu 'lost' to the perfusate was taken to have been absorbed and this was expressed as a percentage of that entering the test segment.
Patients and subjects
The subjects studied were volunteers, in three groups: seven normal subjects, six patients with untreated coeliac disease and three patients with treated coeliac disease. All gave informed consent for the procedure to be carried out.
Results
The absorption of PteGlu in patients with untreated coeliac disease was 23.7 f 4 . 4 % (mean ~S E M ) . This was significantly less than the absorption of PteGlu in normal subjects and in patients with treated coeliac disease: 46.1 f 8.6% and 62.0 f 10.1 % respectively (P < 0.02, Student's t-test) ( Fig. 1) . This confirms the frequency of PteGlu malabsorption in untreated coeliac disease and demonstrates the validity of the test method. The water absorption in the normal group was 123.6 f 33.6 ml/h (mean ~S E M ) . The patients with coeliac disease showed decreased water absorption in comparison, the group as a whole showing net secretion of 43.8 f 35.4 mllh (mean f SEM). This difference was statistically significant (P < 0.01). The water absorption in the patients with treated coeliac disease was very similar to that in the normal subjects, 114.6 f 93.0 mllh (these patients were not compared with the other groups statistically as numbers were small).
During the alkaline phase, the pH change was not entirely predictable, presumably owing to differences in handling of hydroxide ions. There was a wide range of pH during this phase; the subjects who received the higher concentration of sodium hydroxide had the most alkaline jejunal contents ( Table 1) .
In four of the subjects there was no appreciable pH change, but in twelve subjects there was a pH change greater than 1 pH unit; these included normal subjects and patients with coeliac disease, treated and untreated. The twelve subjects showed a significant decrease in absorption of PteGlu from 40.7 46.9% to 22.5 k 6.3 % after alkalinization. This change was significant statistically (P <0.01, paired t-test) ( Table   2 ).
Water absorption for the twelve subjects as a group did not differ significantly during alkalinization: 55.6441.1 d / h , falling slightly to 4.7k47.6 ml/h (P>O.2). In four subjects there was an appreciable decrease in water absorption. The decrease in absorption of PteGlu on alkalinization in the remaining eight subjects, 42.7 +-8.2% to 30.2 +-8.1 %, was still statistically significant (P < 0.025) ( Table 2 ).
The mean pH of the resting jejunal contents (before perfusion) was 6.68 in normal subjects, 6.44 in all patients with coeliac disease and 6.08 in patients with untreated coeliac disease ( Table 1) . The mean pH of jejunal contents during the baseline perfusion was closely similar: normal subjects 6.52, untreated coeliac disease patients 6.53.
Discussion
The findings of this study are, first, that PteGlu malabsorption in patients with coeliac disease is not due to abnormally high jejunal pH; we have shown that, at similar pH, patients with coeliac disease did not absorb as much PteGlu as normal subjects and that the mean resting jejunal pH of patients with coeliac disease is not more alkaline than that of normal subjects. Secondly, we have found that PteGlu absorption in both normal subjects and patients with coeliac disease is decreased by artificially raising the jejunal pH. This confirms the findings of Benn et al. PteGlu may be absorbed in one of two ways: by passive diffusion or by an active process at specific receptor sites. As the small intestine is relatively impermeable to the dissociated form of weak acids (Hogben et al., 1959) , PteGlu, which is itself a weak acid, would need to be at least partly in the undissociated form in order to be absorbed. As PteGlu is fully dissociated above pH 6 (Blair & Matty, 1974) and the normal range of jejunal pH is above 6 (Table 1 ; Benn & Cooke, 1971), its absorption by the process of diffusion would require the presence of an acid microclimate next to the mucosal cell border. This acid microclimate, which has been postulated elsewhere to explain the absorption characteristics of weak acids (Hogben et al., 1959) , would decrease the degree of dissociation of PteGlu and thus allow its diffusion across the cell membrane.
Alternatively, PteGlu may be absorbed actively at specific receptor sites (McIntyre et al., 1975) . The receptor site theory is supported by evidence of saturability (Burgen & Goldberg, 1962) , a hexose and energy requirement (Cooper & Girey, 1970; Gerson, Cohen, Brown, Lindenbaum, Hepner & Janowitz, 1974) and apparent stereo-specificity of uptake for 5-methyltetrahydro-PteGlu in man (Weir, Brown, Freedman & Scott, 1973) . However, this evidence (except for stereo-specificity) may also be explained by the alternative mechanism of passive diffusion : saturability of absorption would be explained by low PteGlu solubility in the postulated acid microclimate and the hexose-energy requirement may be necessary to maintain the acid microclimate. The stereo-specificity for 5-methyltetrahydro-FYeGlu reported by Weir and co-workers would seem to support a specific receptor site theory.
However, the conclusions drawn from these findings have been contested because of dissimilarities in the doses of active and inactive stereo-isomers given in these experiments (Blair & Matty, 1974) .
The effect of increasing jejunal pH, as in our present study, would predictably affect the postulated acid microclimate by making it more alkaline. This would increase the proportion of dissociated PteGlu in the microclimate and thus decrease the amount of the undissociated form, the form in which it is diffusible. Decreased absorption of PteGlu by increasing pH may also be explained by the receptor site theory: altering pH would affect the affinity of the receptor sites for PteGlu by changes in the electrical configuration of the PteGIu and/or the receptor sites themselves. The resultant effect on this pH change on these two variables is therefore not so clearly predictable as with the acid microclimate theory.
The measurement of water absorption in the human jejunum by the triple-lumen method and by the double-lumen method with proximal occluding balloons is well established (Cooper, Levitan, Fordtran & Ingelfinger, 1966; Whalen, Harris, Greenan & Soergel, 1966; Phillips & Summerskill, 1966) . Our results for net water absorption in normal subjects in this study are of the same order as those we found in previous studies with a perfusion technique (Russell, Allan, Gerskowitch & Robertson, 1972; Russell, Allan, Gerskowitch & Cochran, 1973 ; MacKenzie, Cochran & Russell, 1975) . The net secretion of water in the jejunum in patients with untreated coeliac disease confirms the previous findings in this condition (Schmid, Phillips & Summerskill, 1969; Russell et al., 1972) . This net secretion of water in patients with coeliac disease may well be partly, if not entirely, responsible for their PteGlu malabsorption.
The effect of alkali on water absorption in man has not previously been studied. Our results suggest that there is no consistent effect on water absorption of alkaline pH between pH 7 and pH 9. Above pH 9, four subjects out of seven showed an appreciable decrease (or increasing net secretion) of water absorption.
Thus it appears that artificial alkalinization, whilst not reducing water absorption significantly, nevertheless decreases absorption of PteGlu. In the four subjects (J.C., A.G., M.S. and S.D.) who did show an appreciable decrease in water absorption there was a very marked decrease in absorption of PteGlu and these had amongst the highest artificially increased jejunal pH. In these subjects, decreased water absorption can be incriminated in the PteGlu malabsorption, but not in the other eight, in whom no appreciable change of water absorption occurred on alkalinization.
The method of small-intestinal perfusion lends itself well to the study of the absorption of solutes. Absorption of PteGlu was measured in 1968 with a double-lumen tube and PteGlu measured by microbiological assay (Hepner, Booth, Cowan, Hoff brand & Mollin, 1968) . More recently 3H-labelled PteGlu, together with a more accurate triple-lumen tube, was used to assess absorption of ReGlu (Gerson, Hepner, Brown, Cohen, Herbert & Janowitz, 1972) . The results for absorption of PteGlu obtained by these two groups were similar to our own. Our results are more strictly comparable with those of Gerson and co-workers as the technique was similar, though our figures for PteGlu absorption in normal subjects are slightly higher. This is probably due to an inherent over-estimation of water absorption when phenolsulphonphthalein is used as a watersoluble marker: intestinal mucoproteins 'mimic' this agent in that a falsely high reading of absorbance may be obtained when phenolsulphonphthalein is measured spectrophotometrically (MacGregor & Meyer,
974).
This method for estimating absorption of PteGlu assures that disappearance from the lumen of 3H-labelled PteGlu is equivalent to its absorption. This may not be acceptable after a single oral dose but is acceptable if a steady state is established, as was the case in our study.
As there was a considerable overlap in the absorption of PteGlu in normal subjects and patients with untreated coeliac disease, this method is not a promising one for the routine assessment of absorption of PteGlu, although further work is needed. This is in progress in patients with coeliac disease and other groups.
